

# Valued Outcomes in the Cancer Experience: Patient Priorities and Control

Alexandra K. Zaleta, PhD<sup>1</sup>, Shauna McManus, BS<sup>1</sup>, Mellissa F. Miller, PhD, MPH<sup>1</sup>, Eva Yuen, PhD<sup>1</sup>, Kevin Stein, PhD, FAPOS<sup>1</sup>, Karen Hurley, PhD<sup>2</sup>, Lillie D. Shockney, RN, BS, MS<sup>3</sup>, Sara Goldberger, LCSW-R<sup>4</sup>, Mitch Golant, PhD<sup>1</sup>, Joanne S. Buzaglo, PhD<sup>1</sup>

<sup>1</sup>Cancer Support Community, Research and Training Institute, Philadelphia PA; <sup>2</sup>Center for Behavioral Health, Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, OH; <sup>3</sup>Johns Hopkins Breast Center, Johns Hopkins School of Medicine, Baltimore, MD; <sup>4</sup>Cancer Support Community, New York, NY

## Background

- In the era of value-based cancer care, identifying what is important to cancer survivors, and their perceived control over these experiences, can inform shared decision-making and support quality care.

## Aims

- The objective of this study was to examine cancer patient priorities and control to guide the development of a new measure of patient value, Valued Outcomes in the Cancer Experience™(VOICE).

## Methods

- 459 cancer survivors completed an online survey, provided demographic and health history, and rated (0=Not at all; 4=Very much) their level of importance and control over 54 value items.
- Items of most and least importance (I), items with most and least control (C), and rating discrepancies (importance-control) were identified.
- Bivariate associations between items with high importance/control discrepancies and socio-demographic and clinical variables were assessed using ANOVA and pairwise post-hoc analyses.


## Participants

	N = 459	Mean / n	SD / %
Age		60 years	10
		Range: 29 – 83 years	
Female	362		79%
Non-Hispanic White	384		86%
Diagnosis			
Breast	172		38%
Blood	81		18%
Lung	43		9%
Prostate	42		9%
Ovarian	20		4%
Other	101		22%
Time Since Diagnosis		6.5 years	5.5
		Range: 0 – 41 years	
Current Disease Status			
Metastatic	98		22%
Recurrence/Relapse	83		19%
Remission	239		54%
Treatment History			
Surgery	352		80%
Chemotherapy (past / current)	280 / 81		67% / 23%
Radiation therapy (past / current)	244 / 8		60% / 2%
Hormonal therapy (past / current)	106 / 87		29% / 24%


## Results

### Items of Highest Importance and Control


#### Highest Importance:



#### Highest Control:



- For each item, participants were asked, "Today, how important to you is..." and "Today, how much can you control..."



### Greatest Discrepancies between Level of Importance and Control

Items	% Important	% Control	Mean I-C	SD I-C
Having your illness not get worse or come back	96	27	2.05	1.34
Having energy to do things that are important to you	98	41	1.48	1.15
Being able to afford medical expenses	96	49	1.44	1.32
Having a death free from suffering	91	40	1.42	1.38
Having your medical providers communicate with each other about your care	94	44	1.36	1.31

- Mean/SD discrepancies are based on raw item ratings (0=Not at all; 4=Very much).

### Associations with Greater Importance-Control Discrepancies

Items	F(df)	p
<b>Having your illness not get worse or come back</b>		
Poor general health	6.31 (4,424)	<.001
<b>Having energy to do things that are important to you</b>		
Low income	8.32 (2,444)	<.001
Unemployment, disability	7.93 (4,444)	<.001
Poor general health	16.09 (4,429)	<.001
<b>Being able to afford medical expenses</b>		
Low income	15.70 (2,440)	<.001
Unemployment, retired	9.07 (4,440)	<.001
Poor general health	10.13 (4,424)	<.001
<b>Having a death free from suffering</b>		
Unemployment, disability	3.51 (4,438)	<.005
Poor general health	5.43 (4,422)	<.001
<b>Having your medical providers communicate with each other about your care</b>		
Poor general health	6.06 (4,428)	<.001

- Greater discrepancies between level of importance and level of control were associated with lower income, unemployment due to retirement or disability, and poorer health.

## Implications and Conclusions

- Cancer patients experience notable discrepancies between personal priorities and their ability to control these experiences.
- Areas for potential intervention include fear of recurrence, fatigue, financial and end of life issues.
- Interventions should be targeted towards patients with poorer health and fewer economic resources.
- Next steps include psychometric assessment to refine the VOICE scale to guide clinical and research efforts to improve patient care outcomes.

## Acknowledgments

This work is made possible thanks to generous support from Pfizer Oncology.

## References

- DeRouen, M. C., Smith, A. W., Tao, L., Bellizzi, K. M., Lynch, C. F., Parsons, H. M., . . . Keegan, T. H. M. (2015). Cancer-related information needs and cancer's impact on control over life influence health-related quality of life among adolescents and young adults with cancer. *Psycho-Oncology*, 24(9), 1104-1115.
- Finset, A. (2017). Patients' values and preferences and communication about life expectancy: Combining honesty and hope. *Patient Educ Couns*, 100(10), 1777.
- Alidina, K., & Tetters, I. (2010). Exploring the therapeutic value of hope in palliative nursing. *Palliat Support Care*, 8(3), 353-358. doi:10.1017/s1478951510000155
- Olver, I. N. (2012). Evolving definitions of hope in oncology. *Curr Opin Support Palliat Care*, 6(2), 236-241. doi:10.1097/SPC.0b013e3283528d0c